Molecular Partners Reports Nine Active Trial Sites And Ongoing Treatment In Phase 2 MP0317 Cholangiocarcinoma Study, With Data Update Expected In 2027 And Completion In 2028

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing
Data update expected in 2027, with trial completion in 2028
Trial-in-progress poster to be presented at ESMO 2026 in October

Comments

No comments yet. Be the first!